| 159.61 8.1 (5.35%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 199.7 |
1-year : | 233.25 |
| Resists | First : | 170.97 |
Second : | 199.7 |
| Pivot price | 150.33 |
|||
| Supports | First : | 152.22 |
Second : | 140.63 |
| MAs | MA(5) : | 150.8 |
MA(20) : | 150.53 |
| MA(100) : | 209.89  |
MA(250) : | 270.48 |
|
| MACD | MACD : | -6.2 |
Signal : | -8.9 |
| %K %D | K(14,3) : | 75.4 |
D(3) : | 56.6 |
| RSI | RSI(14): 51.6 |
|||
| 52-week | High : | 354.88 | Low : | 140.63 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PODD ] has closed below upper band by 8.5%. Bollinger Bands are 30.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 161.05 - 161.69 | 161.69 - 162.24 |
| Low: | 147.49 - 148.24 | 148.24 - 148.89 |
| Close: | 158.25 - 159.53 | 159.53 - 160.64 |
Insulet Corporation specializes in the creation, production, and distribution of advanced insulin management systems for individuals living with insulin-dependent diabetes. At the core of their offerings is the Omnipod System, an innovative solution featuring a unique, self-adhesive, and disposable Omnipod device. This tubeless unit can be directly applied to the body for a duration of up to three days, and it operates in conjunction with a wireless handheld personal diabetes manager. The company's products reach customers predominantly through independent distributors and pharmaceutical channels, though direct sales also occur. Geographically, Insulet serves markets spanning the United States, Canada, Europe, the Middle East, and Australia. Established in 2000, the corporation's headquarters are located in Acton, Massachusetts.
Tue, 09 Jun 2026
Insulet Corp (PODD) Shares Surge 5.3% -- What GF Score of 82 Tel - GuruFocus
Tue, 09 Jun 2026
Insulet Jumps 5.4% Amid Sector-Wide Rally - AlphaStreet
Tue, 09 Jun 2026
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
Tue, 09 Jun 2026
Raymond James Sticks to Their Buy Rating for Insulet (PODD) - The Globe and Mail
Mon, 08 Jun 2026
Insulet Corporation Valuation Pressure Has Dropped Enough (Upgrade) (NASDAQ:PODD) - Seeking Alpha
Mon, 08 Jun 2026
Assessing Insulet (PODD) Valuation After New Omnipod 6 And Closed Loop Diabetes Data - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 69 (M) |
| Shares Float | 69 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 105.3 (%) |
| Shares Short | 3,010 (K) |
| Shares Short P.Month | 2,700 (K) |
| EPS | 4.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 21.53 |
| Profit Margin | 10.4 % |
| Operating Margin | 16 % |
| Return on Assets (ttm) | 9.7 % |
| Return on Equity (ttm) | 23 % |
| Qtrly Rev. Growth | 33.9 % |
| Gross Profit (p.s.) | 29.74 |
| Sales Per Share | 41.87 |
| EBITDA (p.s.) | 8.69 |
| Qtrly Earnings Growth | 159 % |
| Operating Cash Flow | 619 (M) |
| Levered Free Cash Flow | 253 (M) |
| PE Ratio | 37.29 |
| PEG Ratio | 1.1 |
| Price to Book value | 7.41 |
| Price to Sales | 3.81 |
| Price to Cash Flow | 17.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|